Given the shared genetic predisposition at the extended CFH locus with AMD, it is tempting to speculate that emerging treatments that target CFH downstream C3 and C5 for treatment of AMD may be repurposed for management of idiopathic MFC.45,46 However, future research should determine the involvement of C3 and C5 in idiopathic MFC disease mechanisms. The gene discussed is C5; the disease is age-related macular degeneration.